YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
By Steven Ralston, CFA NYSE: VNRX READ THE FULL VNRX RESEARCH REPORT EXECUTIVE OVERVIEW VolitionRx Limited (NYSE: VNRX) continues to advance its multi-pillar epigenetics platform through mid-2026, generating a continued stream of clinical…
By Steven Ralston, CFA NYSE: VNRX READ THE FULL VNRX RESEARCH REPORT EXECUTIVE OVERVIEW VolitionRx Limited (NYSE: VNRX) continues to advance its multi-pillar epigenetics platform through mid-2026, generating a continued stream of clinical…
Image source: The Motley Fool. DATE Friday, Aug. 14, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Group Chief Marketing and Communications Officer - Louise Batchelor Group Chief Executive Officer - Cameron Reynolds Group Chief Financial Officer…
With an upside potential of 1451.32%, VolitionRx Limited (NYSEAMERICAN:VNRX) is among the 7 Best Rated Penny Stocks to Buy According to Wall Street Analysts. On May 15, Cameron Reynolds, President and Group Chief Executive Officer of Volit…
Earnings Call Insights: VolitionRx Limited (VNRX) Q1 2026 MANAGEMENT VIEW * "From a revenue perspective, we recorded approximately $1 million in the first quarter compared to approximately $0.2 million in the same period of 2025" (CFO Teri…
Earnings Call Insights: VolitionRx (VNRX) Q4 2025 MANAGEMENT VIEW * CEO Cameron Reynolds said Q4 2025 included “our first order for the new Nu.Q Cancer assays for clinical certification ahead of routine clinical use in lung cancer” and “th…
(RTTNews) - VolitionRx Limited's (VNRX) breakthrough liquid biopsy technology, Capture-Seq, has delivered striking proof-of-concept results, detecting more than 95% of stage I and stage II cancers in a blinded validation cohort. The compan…
* VolitionRx (VNRX [https://seekingalpha.com/symbol/VNRX]) entered [https://seekingalpha.com/pr/20358137-volitionrx-secures-2_0-million-in-funding] into an amended and restated securities purchase agreement with Lind Global Asset Managemen…
HENDERSON, Nev., Dec. 4, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the inclusion of its Nu.Q® NETs H3.1 assay in "DETECSEPS", a real-world evaluation o…
By Steven Ralston, CFA NYSE:VNRX READ THE FULL VNRX RESEARCH REPORT EXECUTIVE SUMMARY VolitionRx’s (NYSE:VNRX): Management’s primary operational goal for 2025 is to secure multiple licensing agreements for human diagnostic applications. In…
This article first appeared on GuruFocus. Release Date: November 14, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points VolitionRX Ltd (VNRX) signed two significant agr…
Earnings Call Insights: VolitionRx Limited (VNRX) Q3 2025 MANAGEMENT VIEW * Cameron Reynolds, CEO, announced, "2025 efforts for Volition have focused on commercializing our groundbreaking Nu.Q platform in the human diagnostic market, and w…
Conference call to discuss financial and operational results scheduled for Friday, November 14 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nevada, Nov. 13, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-n…
* VolitionRx (NYSE:VNRX [https://seekingalpha.com/symbol/VNRX]) on Friday announced the pricing of an underwritten public offering of 11.5M shares of its common stock and warrants to purchase up to 11.5M shares of its common stock. * The p…
* VolitionRx (NYSE:VNRX [https://seekingalpha.com/symbol/VNRX]) is proposing to offer and sell, in an underwritten public offering, shares of its common stock and accompanying common stock purchase warrants. * The final terms of the propos…
By Steven Ralston, CFA NYSE:VNRX READ THE FULL VNRX RESEARCH REPORT SIGNIFICANT RECENT NEWS VolitionRx’s (NYSE:VNRX) announcements of two significant licensing agreements in September 2025 represent the materialization of a key priority th…
HENDERSON, Nev., Sept. 29, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that it has signed an agreement with Hologic Diagenode ("Hologic") for the co-mark…
(RTTNews) - Biotech stocks are showing renewed momentum, with several small-cap names posting notable after-hours gains and attracting investor attention. From insider buying and strategic partnerships to clinical trial progress and bold f…
(RTTNews) - VolitionRx Limited (VNRX), a multinational epigenetics company, has signed a Research License and Exclusive Commercial Option Rights Agreement with Werfen's Immunoassay Technology Center to advance diagnostics for Antiphospholi…
Investing.com - Volitionrx Ltd (NYSE: VNRX) reported second quarter EPS of $-0.060, $0.01 worse than the analyst estimate of $-0.047. Revenue for the quarter came in at $406.69K versus the consensus estimate of $537.62K. Volitionrx Ltd’s s…
* VolitionRX press release [https://seekingalpha.com/pr/20201938-volitionrx-limited-announces-second-quarter-2025-financial-results-and-business-update] (NYSE:VNRX [https://seekingalpha.com/symbol/VNRX]): Q2 Recorded just over $0.4 million…
* VolitionRx (NYSE:VNRX [https://seekingalpha.com/symbol/VNRX]) filed a prospectus to sale 23.44 million shares of common stock. * The company will not receive any proceeds from the sale of ordinary shares by the selling shareholder. * Thi…
HENDERSON, Nev., June 23, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announced today that the underwriters of its previously announced underwritten public offering of i…
By Steven Ralston, CFA NYSE:VNRX READ THE FULL VNRX RESEARCH REPORT Highlights of Annual Capital Markets Day On May 11, 2023, VolitionRx (NYSE:VNRX) conducted the company’s Annual Capital Markets Day. The presentations included the current…
HENDERSON, Nev., June 5, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announced today the closing of its previously announced underwritten public offering of its common s…
HENDERSON, Nev., June 1, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today the pricing of an underwritten public offering of 13,000,000 shares…
HENDERSON, Nev., May 31, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it has commenced an underwritten public offering of shares of…
HENDERSON, Nev. , May 11, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces new research - published in PLOS ONE - which reveals that plasma nucleosome concentration…
Conference call to discuss financial and operational results scheduled for Thursday, May 11, at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev., May 10, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced…
Conference call to take place on Thursday May 11 at 08:30 a.m. Eastern Time Capital Markets Day - Thursday May 11 at 2:00 p.m. Eastern Time HENDERSON, Nev., May 5, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition")…
HENDERSON, Nev., April 26, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company is hosting a Capital Markets Day in a hybrid format (in-person and live-webcast) on Thursday, May 1…
LAS VEGAS, NV / ACCESSWIRE / April 24, 2023 / Planet MicroCap presents the Planet MicroCap Showcase: VEGAS taking place on April 25-27, 2023, where 77 MicroCap public and private companies will be presenting at the Horseshoe Hotel & Casino…
Conference call to discuss financial and operational results scheduled for Thursday, March 16, at 8:30 a.m. U.S. Eastern Time Executed global licensing and supply agreement with Heska Corporation ("Heska") to distribute Nu.Q® Vet Cancer Te…
Virtual Investor Conferences Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com NEW YORK, March 10, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference seri…
Conference call to take place on Thursday March 16 at 08:30 a.m. Eastern Time HENDERSON, Nev., March 10, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Thursday…
Virtual Investor Conferences Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com NEW YORK, March 07, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference…